Monopar Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Monopar Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

September 05, 2023 | Last Trade: US$5.71 0.56 10.87

WILMETTE, Ill., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler D. Robinson, MD, Monopar’s Chief Executive Officer, will present at the H.C. Wainwright 25^th Annual Global Investment Conference. The Company’s presentation will be webcast beginning on Monday, September 11, 2023 at 7:00 a.m. ET. In person one-on-one meetings will take place at the Lotte New York Palace, NY, NY from September 11 - 13, 2023.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR-101, a late-stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR-202, an early-stage camsirubicin analog for various cancers. For more information, visit: www.monopartx.com.

CONTACT:

Monopar Therapeutics Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics

Stock Quote

Last Trade:	US$5.71
Daily Change:	0.56 10.87
Daily Volume:	56,707
Market Cap:	US$20.100M

October 15, 2024 Monopar Therapeutics Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers October 07, 2024 Monopar Therapeutics Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers September 12, 2024 Monopar Therapeutics Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr August 21, 2024 Monopar Therapeutics Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers August 14, 2024 Monopar Therapeutics Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr LOAD MORE NEWS

Featured Stock

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE